Key Highlights
- ViroCell Biologics completes oversubscribed convertible note offering.
- Proceeds to accelerate growth in viral vector design and manufacturing.
- First Light Asset Management leads the new round of investments.
- Significant demand for ViroCell’s GMP viral vector services continues to rise.
Source: Business Wire
Notable Quotes
- “We have been making significant strides commercially and are very pleased to see increasing demand for our differentiated viral vector service offering.” — John W. Hadden II, CEO at ViroCell Biologics
- “We have been impressed with the team at ViroCell and look forward to supporting them on their ambitious growth journey.” — Matt Arens, CEO at First Light Asset Management LLC
SoHC's Take
The successful completion of an oversubscribed convertible note offering marks a significant milestone for ViroCell Biologics, underscoring strong investor confidence in its strategic direction and unique market position. This influx of capital will not only bolster ViroCell’s ability to meet rising demand but also solidify its reputation as a leading CDMO in the cell and gene therapy sector. The involvement of First Light Asset Management signals a robust endorsement of ViroCell’s growth potential and its capacity to deliver high-quality GMP viral vectors crucial to advancing innovative therapies.
